John Gu

Dr. John Gu, founder of Renascions and Renascions Pharmaceuticals II, is an adjunct professor at Molecular Pharmacology Department at City of Hope, and was a faculty member and a program director at Sidney Kimmel Cancer Center.  Dr. Gu was the recipient of the NIH Fellowship for the Human Genome Project at Washington University in St Louis. He was trained in the Human Genome Project (HGP) and worked on the discovery and applications of genome-wide SNPs (single nucleotide polymorphisms) as biomarkers.  His most recent scientific focuses include developing clinical applications using GWAS SNP data based on Renascions' proprietary technology, ReAL.  ReAL has been used in various clinical programs in collaborations with industrial partners, and has achieved outstanding results.  Renascions is also transforming itself into a drug development company, while continue to serve its partners.  Dr. Gu previously worked as a senior scientific staff and section head at Motorola Life Sciences, and as an executive at Vita Genomics, Shanghai GeneCore Biotechnologies, and CytoPharm Therapeutics.  He has extensive knowledge and broad relationships with CFDA for new drug development in China.